Skip to main content

Grafa News and Videos — Page 962

Grafa Headlines

Latest

Grafa

Gilead Sciences gains EU approval for Trodelvy in first-line metastatic TNBC

Gilead Sciences (NASDAQ:GILD) announced that the European Commission has granted marketing authorization for Trodelvy (sacituzumab govitecan-hziy) as monotherapy for adult patients with unresectable or metastatic triple-negative breast cancer who have not received prior systemic therapy and are not candidates for PD-1 or PD-L1 inhibitor treatment.

Read more: Gilead Sciences gains EU approval for Trodelvy in first-line metastatic TNBC

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift